Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies
Posted inClinical Updates Infectious Diseases news Public Health

Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies

This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies and patient management.
Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection
Posted inInfectious Diseases news

Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection

A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑inferior to 14 days for 90‑day mortality.
Targeted Vaccination Is Most Efficient but Not Cost‑Effective: National Serosurvey and Modelling of Japanese Encephalitis in Bangladesh
Posted inInfectious Diseases Neurology news Public Health

Targeted Vaccination Is Most Efficient but Not Cost‑Effective: National Serosurvey and Modelling of Japanese Encephalitis in Bangladesh

A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not cost-effective under conventional thresholds.
Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
Posted inCritical Care Infectious Diseases news Pediatrics Public Health Respiratory

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications

A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlights stewardship and surveillance priorities.
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Posted inInfectious Diseases news Pediatrics

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
Posted inClinical Updates Infectious Diseases news Public Health Respiratory

Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation

This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the clinical impact of high-dose adjuvanted vaccines.
Remote Cognitive Training, Structured Rehabilitation and tDCS Failed to Improve Self‑Reported Cognitive Symptoms in Long COVID: Results from a 5‑Arm Phase 2 Randomized Trial
Posted inInfectious Diseases Internal Medicine Neurology news

Remote Cognitive Training, Structured Rehabilitation and tDCS Failed to Improve Self‑Reported Cognitive Symptoms in Long COVID: Results from a 5‑Arm Phase 2 Randomized Trial

A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑reported cognitive symptoms in long COVID.
GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III
Posted inInfectious Diseases news Public Health

GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III

A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide) with once‑daily lumefantrine and shows promise against partially resistant strains and gametocytes.
Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial
Posted inHIV/AIDS Infectious Diseases news

Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial

In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑making for maintenance regimen selection.
A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7
Posted inHIV/AIDS Infectious Diseases news

A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7

In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage compared with currently licensed vaccines.
Cefiderocol Non‑Inferior to Standard Therapy for Hospital‑Acquired Gram‑Negative Bacteraemia: Insights from the GAME CHANGER Trial
Posted inCritical Care Infectious Diseases news

Cefiderocol Non‑Inferior to Standard Therapy for Hospital‑Acquired Gram‑Negative Bacteraemia: Insights from the GAME CHANGER Trial

The GAME CHANGER randomized trial found cefiderocol non‑inferior to standard‑of‑care antibiotics for 14‑day mortality in hospital‑acquired and healthcare‑associated Gram‑negative bloodstream infection; no superiority was seen, including in carbapenem‑resistant infections.